NL-OMON29139已完成不适用
A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009).
VU University Medical Center, Amsterdam0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients at least 18 years of age;
- •2. At diagnosis chronic myeloid leukemia in chronic phase;
排除标准
- •1. Prior accelerated phase or blast crisis;
- •2. Patient has received another investigational agent within last 6 months;
研究者
相似试验
已完成
2 期
A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon *2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)10024324Chronic Myeloid LeukemiaCMLNL-OMON41622Vrije Universiteit Medisch Centrum17
进行中（未招募）
1 期
a study to investigate combination treatment of nilotinib and pegylated interferon a2b in patients with a suboptimal molecular response after at least two years of imatinib treatmentChronic myeloid leukemia in chronic phase and = 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).MedDRA version: 17.0Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2012-004321-25-SEVU University Medical Center60
进行中（未招募）
1 期
a study to investigate combination treatment of nilotinib and pegylated interferon a2b in patients with a suboptimal molecular response after at least two years of imatinib treatmentChronic myeloid leukemia in chronic phase and = 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).MedDRA version: 18.0Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2012-004321-25-NLVU University Medical Center30
进行中（未招募）
1 期
a study to investigate combination treatment of nilotinib and pegylated interferon a2b in patients with a suboptimal molecular response after at least two years of imatinib treatmentChronic myeloid leukemia in chronic phase and = 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level between 0.01% and 1% IS).MedDRA version: 15.1Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2012-004321-25-NOVU University Medical Center60
进行中（未招募）
不适用
An open label, single arm, phase II study of nilotinib 300 mg BID in newly diagnosedCP-CML patients, in order to verify disappearance of CD34+/lin-Ph+ cells from bone marrowduring treatment.newly diagnosed CP-CML patientsMedDRA version: 14.1Level: LLTClassification code 10052065Term: Chronic phase chronic myeloid leukaemiaSystem Organ Class: 100000004864EUCTR2012-005062-34-ITAZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)